Do analysts prefer SBTX or TBPH?

Theravance Biopharma has a consensus target price of $19.40, suggesting a potential upside of 14.66%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Theravance Biopharma is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Theravance Biopharma 0 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.25

Do analysts prefer SBTX or AMPH?

Amphastar Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 5.47%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Amphastar Pharmaceuticals 2 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Do analysts rate SGP or SBTX?

Spyglass Pharma currently has a consensus target price of $44.00, suggesting a potential upside of 70.67%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Spyglass Pharma is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyglass Pharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, SGP or SBTX?

Spyglass Pharma is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is SGP or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Spyglass Pharma N/A -62.40% -24.83% Silverback Therapeutics N/A -29.62% -28.20%

Do analysts recommend SBTX or ESPR?

Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 74.21%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Esperion Therapeutics 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate SBTX or HELP?

Cybin has a consensus price target of $45.25, indicating a potential upside of 291.10%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cybin 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings and valuation, SBTX or HELP?

Cybin is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Cybin N/A N/A -$148M -$4.23 N/A

Is SBTX or HELP more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Cybin N/A -74.05% -66.08%

Silverback Therapeutics (SBTX) Competitors

$5.65 -0.45 (-7.38%)

As of 08/14/2026

Compare

SBTX vs. TBPH, AMPH, SGP, ESPR, and HELP

Should you buy Silverback Therapeutics stock or one of its competitors? Silverback Therapeutics's main competitors and comparable companies include Theravance Biopharma (TBPH), Amphastar Pharmaceuticals (AMPH), Spyglass Pharma (SGP), Esperion Therapeutics (ESPR), and Cybin (HELP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Silverback Therapeutics compare to Theravance Biopharma?

Silverback Therapeutics (NASDAQ:SBTX) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Theravance Biopharma has a net margin of 51.58% compared to Silverback Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of -0.77% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Theravance Biopharma has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Theravance Biopharma	$107.46M	8.18	$105.89M	$1.01	16.75

Theravance Biopharma has a consensus target price of $19.40, suggesting a potential upside of 14.66%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Theravance Biopharma is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Theravance Biopharma	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.25

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Theravance Biopharma had 4 more articles in the media than Silverback Therapeutics. MarketBeat recorded 4 mentions for Theravance Biopharma and 0 mentions for Silverback Therapeutics. Theravance Biopharma's average media sentiment score of 0.57 beat Silverback Therapeutics' score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Theravance Biopharma	Positive

Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Summary

Theravance Biopharma beats Silverback Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Silverback Therapeutics compare to Amphastar Pharmaceuticals?

Silverback Therapeutics (NASDAQ:SBTX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Silverback Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Amphastar Pharmaceuticals has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Amphastar Pharmaceuticals	$719.89M	1.23	$98.09M	$1.69	12.34

Amphastar Pharmaceuticals has a consensus price target of $22.00, indicating a potential upside of 5.47%. Given Amphastar Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Amphastar Pharmaceuticals is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Amphastar Pharmaceuticals had 12 more articles in the media than Silverback Therapeutics. MarketBeat recorded 12 mentions for Amphastar Pharmaceuticals and 0 mentions for Silverback Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.40 beat Silverback Therapeutics' score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Amphastar Pharmaceuticals	Neutral

Summary

Amphastar Pharmaceuticals beats Silverback Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Silverback Therapeutics compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Spyglass Pharma currently has a consensus target price of $44.00, suggesting a potential upside of 70.67%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Spyglass Pharma is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Silverback Therapeutics' return on equity of -29.62% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
Silverback Therapeutics	N/A	-29.62%	-28.20%

74.9% of Silverback Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Spyglass Pharma had 15 more articles in the media than Silverback Therapeutics. MarketBeat recorded 15 mentions for Spyglass Pharma and 0 mentions for Silverback Therapeutics. Silverback Therapeutics' average media sentiment score of 0.00 beat Spyglass Pharma's score of -0.31 indicating that Silverback Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Spyglass Pharma	Neutral
Silverback Therapeutics	Neutral

Spyglass Pharma is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Summary

Spyglass Pharma and Silverback Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Silverback Therapeutics compare to Esperion Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled Esperion Therapeutics'average media sentiment score.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Esperion Therapeutics	Neutral

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Esperion Therapeutics has a consensus price target of $5.54, suggesting a potential upside of 74.21%. Given Esperion Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Esperion Therapeutics has higher revenue and earnings than Silverback Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Silverback Therapeutics' net margin of 0.00%. Esperion Therapeutics' return on equity of -0.14% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Summary

Esperion Therapeutics beats Silverback Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Silverback Therapeutics compare to Cybin?

Silverback Therapeutics (NASDAQ:SBTX) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Silverback Therapeutics' return on equity of -29.62% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Cybin	N/A	-74.05%	-66.08%

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cybin had 5 more articles in the media than Silverback Therapeutics. MarketBeat recorded 5 mentions for Cybin and 0 mentions for Silverback Therapeutics. Silverback Therapeutics' average media sentiment score of 0.00 beat Cybin's score of -0.16 indicating that Silverback Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Cybin	Neutral

Cybin is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Cybin	N/A	N/A	-$148M	-$4.23	N/A

Cybin has a consensus price target of $45.25, indicating a potential upside of 291.10%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Cybin has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

Summary

Silverback Therapeutics beats Cybin on 9 of the 13 factors compared between the two stocks.

Get Silverback Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBTX vs. The Competition

Export

Metric	Silverback Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$203.73M	$11.83B	$7.03B	$13.06B
Dividend Yield	N/A	2.69%	2.56%	10.62%
P/E Ratio	-2.33	779.61	270.85	25.39
Price / Sales	N/A	747.83	597.90	88.46
Price / Cash	N/A	15.03	28.87	38.47
Price / Book	0.76	10.40	11.09	6.51
Net Income	-$89.48M	$2.78B	$3.45B	$347.22M
7 Day Performance	-8.28%	0.15%	0.74%	1.51%
1 Month Performance	-24.26%	0.04%	2.15%	2.74%
1 Year Performance	-61.11%	145.28%	63.00%	21.07%

Silverback Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBTX Silverback Therapeutics	N/A	$5.65 -7.4%	N/A	-61.1%	$203.73M	N/A	N/A	83	High Trading Volume
TBPH Theravance Biopharma	2.8237 of 5 stars	$16.92 flat	$19.40 +14.7%	+29.0%	$872.23M	$107.46M	16.75	110	Earnings Report
AMPH Amphastar Pharmaceuticals	2.7257 of 5 stars	$20.18 +1.0%	$22.00 +9.0%	-29.9%	$858.46M	$719.89M	11.94	1,976
SGP Spyglass Pharma	1.8319 of 5 stars	$25.17 -0.4%	$45.00 +78.8%	N/A	$841.43M	N/A	N/A	65	Analyst Forecast
ESPR Esperion Therapeutics	N/A	$3.18 flat	$5.54 +74.2%	N/A	$819.45M	$403.14M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBTX) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silverback Therapeutics (SBTX) Competitors

SBTX vs. TBPH, AMPH, SGP, ESPR, and HELP

How does Silverback Therapeutics compare to Theravance Biopharma?

Summary

How does Silverback Therapeutics compare to Amphastar Pharmaceuticals?

Summary

How does Silverback Therapeutics compare to Spyglass Pharma?

Summary

How does Silverback Therapeutics compare to Esperion Therapeutics?

Summary

How does Silverback Therapeutics compare to Cybin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silverback Therapeutics (SBTX) Competitors

SBTX vs. TBPH, AMPH, SGP, ESPR, and HELP

How does Silverback Therapeutics compare to Theravance Biopharma?

Is SBTX or TBPH more profitable?

Which has stronger valuation & earnings, SBTX or TBPH?

Do analysts prefer SBTX or TBPH?

Do insiders & institutionals hold more shares of SBTX or TBPH?

Does the media prefer SBTX or TBPH?

Which has more risk and volatility, SBTX or TBPH?

Summary

How does Silverback Therapeutics compare to Amphastar Pharmaceuticals?

Is SBTX or AMPH more profitable?

Which has more risk and volatility, SBTX or AMPH?

Do insiders & institutionals believe in SBTX or AMPH?

Which has better valuation & earnings, SBTX or AMPH?

Do analysts prefer SBTX or AMPH?

Does the media refer more to SBTX or AMPH?

Summary

How does Silverback Therapeutics compare to Spyglass Pharma?

Do analysts rate SGP or SBTX?

Is SGP or SBTX more profitable?

Do institutionals and insiders hold more shares of SGP or SBTX?

Does the media refer more to SGP or SBTX?

Which has preferable valuation & earnings, SGP or SBTX?

Summary

How does Silverback Therapeutics compare to Esperion Therapeutics?

Does the media refer more to SBTX or ESPR?

Do insiders and institutionals hold more shares of SBTX or ESPR?

Which has more risk and volatility, SBTX or ESPR?

Do analysts recommend SBTX or ESPR?

Which has higher earnings & valuation, SBTX or ESPR?

Is SBTX or ESPR more profitable?

Summary

How does Silverback Therapeutics compare to Cybin?

Is SBTX or HELP more profitable?

Do institutionals & insiders believe in SBTX or HELP?

Does the media refer more to SBTX or HELP?

Which has stronger earnings and valuation, SBTX or HELP?

Do analysts rate SBTX or HELP?

Which has more volatility and risk, SBTX or HELP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools